Innovation Ventures Search Results
Narrow Your Results
Filter
Technology PatentStatus
- All (3)
- Issued Patent (1)
- National Phase Entry (2)
- PCT Filing (0)
- Provisional Filing (0)
- US Non-Provisional Filing (0)
Technology Categories
- All (3)
- Diagnostics (0)
- Educational Tools and Consumer Products (0)
- Medical Devices (0)
- Other (0)
- Research Tools (0)
- Software (0)
- Therapeutics (3)
Technology Stage Of Development
- All Results (3)
- Cell and Gene Therapy (0)
- Organoids (0)
- Other Biologics and Macromolecules (0)
- Small Molecule (3)
- Vaccines (0)
Results (3)
Combination Therapy for Leukemia and Solid Tumors
A pharmaceutical therapy that has demonstrated, in vivo, the ability to eliminate leukemic, lung adenocarcinoma and lung squamous carcinoma cells.
Novel Small Molecule RAC-Pathway Inhibitor for the Treatment of Cancer
Our proprietary inhibitor binds to VAV3 thereby inhibiting the activation of RAC downstream of several oncogenes.
Targeted inhibition of UBE2N as a therapeutic approach in myeloid malignancies
Pharmacologic and genetic inhibition of UBE2N suppresses the function and viability of MDS/AML cells lines and patient samples. A commercially available and a novel compound has been identified.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
